Literature DB >> 2423028

High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine.

W P McCann, L M Hall, W Siler, N Barton, R J Whitley.   

Abstract

New high-pressure liquid chromatographic methods for determining concentrations of arabinosyladenine (Ara-A), its 5'-monophosphate (Ara-AMP), and arabinosylhypoxanthine (Ara-H) in plasma and urine are presented. A fluorescence detector is used for Ara-A and Ara-AMP, which are first converted to highly fluorescent derivatives with chloroacetaldehyde. This increases sensitivity greatly over previous methods. The sensitivities of the methods (in micrograms per milliliter) are as follows: in plasma, Ara-AMP, 0.002; Ara-A, 0.0015; and Ara-H, 0.35; and in urine, 9 times these values, respectively. Drug concentration data are also presented, which were obtained after doses of Ara-AMP were given intramuscularly to two patients treated with this drug for severe herpes zoster. One patient was given 13 mg of Ara-AMP per kg of body weight once daily, and the other was given 6.5 mg/kg twice daily. Peak Ara-AMP and Ara-A levels in plasma occurred within 1 h after the doses, and neither exceeded 2 micrograms/ml. Ara-AMP and Ara-A concentrations in plasma fell to less than 0.01 micrograms/ml in both patients by 4 to 6 h after the doses. Peak Ara-H concentrations in plasma occurred within 1 to 2 h after doses and were 21 micrograms/ml in patient 1 and 2. The highest concentration of Ara-AMP in urine was 0.09 micrograms/ml. The highest Ara-A concentration in urine was 62 micrograms/ml, and the highest Ara-H concentration in urine was 1,080 micrograms/ml. An interfering substance of unknown nature, cochromatographing with Ara-H, was encountered sporadically in urine samples. An algorithm based on differential spectrophotometry to identify and correct for this problem is described. Estimates of the renal clearances of Ara-AMP, Ara-A, and Ara-H are also given.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2423028      PMCID: PMC180230          DOI: 10.1128/AAC.28.2.265

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Endogenous creatinine in serum and urine.

Authors:  R S HARE
Journal:  Proc Soc Exp Biol Med       Date:  1950-05

2.  Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole.

Authors:  H Roos; K Pfleger
Journal:  Mol Pharmacol       Date:  1972-07       Impact factor: 4.436

3.  Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate.

Authors:  J K Preiksaitis; B Lank; P K Ng; L Brox; G A LePage; D L Tyrrell
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

4.  Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans.

Authors:  R J Whitley; B C Tucker; A W Kinkel; N H Barton; R F Pass; J D Whelchel; C G Cobbs; A G Diethelm; R A Buchanan
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  Determination of adenosine in normal human plasma and serum by high-performance liquid chromatography.

Authors:  M C Capogrossi; M R Holdiness; Z H Israili
Journal:  J Chromatogr       Date:  1982-01-08

6.  Adenine arabinoside and allopurinol--possible adverse drug interaction.

Authors:  H M Friedman
Journal:  N Engl J Med       Date:  1981-02-12       Impact factor: 91.245

7.  Vidarabine therapy of varicella in immunosuppressed patients.

Authors:  R Whitley; M Hilty; R Haynes; Y Bryson; J D Connor; S J Soong; C A Alford
Journal:  J Pediatr       Date:  1982-07       Impact factor: 4.406

8.  Simple sensitive microbioassay for adenine arabinoside and hypoxanthine arabinoside in human plasma.

Authors:  Y J Bryson; L Sweetman; J D Connor
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

9.  Plasma levels and urinary excretion of vidarabine after repeated dosing.

Authors:  R A Buchanan; A W Kinkel; C A Alford; R J Whitley
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

10.  Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure.

Authors:  G R Aronoff; J J Szwed; R L Nelson; E L Marcus; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

View more
  7 in total

1.  Type 1 ribosome-inactivating proteins are the most abundant proteins in iris (Iris hollandica var. Professor Blaauw) bulbs: characterization and molecular cloning.

Authors:  E J Van Damme; A Barre; L Barbieri; P Valbonesi; P Rouge; F Van Leuven; F Stirpe; W J Peumans
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

2.  High-pressure-liquid-chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin.

Authors:  M Zamboni; M Brigotti; F Rambelli; L Montanaro; S Sperti
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

3.  Polynucleotide: adenosine glycosidase activity of saporin-L1: effect on DNA, RNA and poly(A).

Authors:  L Barbieri; P Valbonesi; P Gorini; A Pession; F Stirpe
Journal:  Biochem J       Date:  1996-10-15       Impact factor: 3.857

4.  Effects of ribosome-inactivating proteins on Escherichia coli and Agrobacterium tumefaciens translation systems.

Authors:  T Girbés; L Barbieri; M Ferreras; F J Arias; M A Rojo; R Iglesias; C Alegre; C Escarmis; F Stirpe
Journal:  J Bacteriol       Date:  1993-10       Impact factor: 3.490

5.  Some ribosome-inactivating proteins depurinate ribosomal RNA at multiple sites.

Authors:  L Barbieri; J M Ferreras; A Barraco; P Ricci; F Stirpe
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

6.  Requirements for the inactivation of ribosomes by gelonin.

Authors:  S Sperti; M Brigotti; M Zamboni; D Carnicelli; L Montanaro
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

7.  Isolation and partial characterization of a new ribosome-inactivating protein from Petrocoptis glaucifolia (Lag.) Boiss.

Authors:  F J Arias; M A Rojo; J M Ferreras; R Iglesias; R Muñoz; A Rocher; E Mendez; L Barbieri; T Girbés
Journal:  Planta       Date:  1992-03       Impact factor: 4.116

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.